Business ❯ Healthcare

Biotechnology

Pharmaceuticals Drug Development Clinical Trials Gene Therapy Cell Therapy Oncology Research and Development Therapeutics Immunotherapy Regulatory Affairs

Cormorant Takes $55 Million Stake in Dianthus After 350% Rally

The disclosure signals rising institutional interest as investors focus on near‑term trial milestones supported by a long cash runway.

Boxer Capital Buys 1.24 Million Vir Biotechnology Shares

ImmunityBio Investors Face May 26 Lead-Plaintiff Deadline in Securities Suit Tied to FDA Anktiva Rebuke

FDA Places Full Clinical Hold on Aardvark’s ARD-101 Prader–Willi Trials

Legend Biotech Q1 Sales Jump on CARVYKTI Growth Despite Expansion-Related Margin Hit

ImmunityBio Investors Face May 26 Deadline in Securities Class Action Over FDA Ad Rebuke

Lifecore Reaffirms 2026 Outlook After Q1 Adds Three Site Transfers

ImmunityBio Securities Fight Intensifies After FDA Rebuke Over Anktiva Claims

Axsome Reports 57% Q1 Sales Jump as FDA Clears Auvelity for Alzheimer’s Agitation

Class Action Filed Against Atara Biotherapeutics Over Alleged Misstatements on FDA Setbacks

ImmunityBio Investors Face May 26 Deadline in Class Action After FDA Flags Misleading Anktiva Claims

Ligand to Buy XOMA Royalty for $739 Million

Sagimet Prices $175 Million Stock Offering as It Plans U.S. Phase 3 Acne Trial

Kailera Leaps 62% in Nasdaq Debut After $625 Million IPO

Cedar Grove’s Q1 Letter Reaffirms Stock-Picking Focus, Highlights Evolv, The RealReal and Abivax

Atara Biotherapeutics Hit With Investor Class Action as Firms Press May 22 Lead-Plaintiff Deadline

ImmunityBio Faces Investor Suits After FDA Rebuke as Anktiva Sales Jump

ImmunityBio Faces Growing Securities Suits After FDA Flags Misleading Anktiva Claims

Investor Class Actions Target Atara Over FDA Setbacks to EBVALLO

ADMA Biologics Denies Short-Seller Report as Shares Rebound and Law Firms Launch Probes